Law360, San Diego (March 29, 2012, 9:55 PM EDT) -- Nearly 100 pending actions accusing Pfizer Inc. of failing to adequately warn pregnant women that antidepressant Zoloft could cause birth defects should be centralized in the Southern District of New York, the New York-based drugmaker told a federal panel Thursday.
Pfizer's attorney Mark Cheffo of Skadden Arps Slate Meagher & Flom LLP said at a hearing before the U.S. Judicial Panel on Multidistrict Litigation that there are 95 actions across 16 federal courts bringing similar claims over Zoloft, up from 59 actions in seven district courts when the company filed its petition for consolidation in January.
“The main dispute is where...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!